Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Therapeutic human papillomavirus vaccines in head and neck cancer: A systematic review of current clinical trials

Publikation: Bidrag til tidsskriftReviewpeer review

  1. Self-reported immunity and opinions on vaccination of hospital personnel among paediatric healthcare workers in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Authors' reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskning

  3. Are refugees arriving in Denmark an under-immunised group for measles? A cross-sectional serology study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Bacille Calmette-Guérin vaccination at birth and differential white blood cell count in infancy. A randomised clinical trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Autologous fibrin sealant co-delivered with antibiotics is a robust method for topical antibiotic treatment after sinus surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. TORS Base-of-Tongue Mucosectomy in Human Papilloma Virus-Negative Carcinoma of Unknown Primary

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Food-SPolypspecific IgE and IgG Antibodies in Patients With Chronic Rhinosinusitis With Nasal: A Case-Control Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Long-term quality of life & functional outcomes after treatment of oropharyngeal cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVES: This systematic review provides an overview of the current clinical trials investigating therapeutic vaccines for HPV+ head and neck cancer and discusses the future directions of therapeutic vaccine therapy.

MATERIALS AND METHODS: A systematic search was conducted in PubMed, EMBASE, Cochrane and clinicaltrials.gov for clinical trials involving therapeutic vaccines. We included studies initiated between 2000 and 2018 with patients diagnosed with HPV+ head and neck cancer and extracted data concerning type of vaccine therapy, adverse events, immunogenicity and clinical outcome measures (e.g. tumour response, progression-free survival and overall survival).

RESULTS: We identified 11 studies (n = 376 patients) initiated between year 2005 and 2017. Four studies (n = 34) presented preliminary results in patients with incurable, recurrent loco-regional or distant metastatic disease indicating a positive immune response with 74% (n = 25/34 patients) having elevated antibody levels, IFN-γ and/or T-cell response. Five studies presented data on the vaccines' safety profile, demonstrating predominantly grade 1 and 2 toxicity. Three studies evaluated the clinical outcome - one study showed no complete or partial response, one study demonstrated stable disease as the best tumour response in 64% (n = 9/14 patients) and one study showed a 33% overall response rate: one patient with a complete response and seven patients with a partial response.

CONCLUSIONS: Treatment with therapeutic vaccines is a promising and seemingly safe strategy for patients with HPV+ head and neck cancer. However, there are not enough data to draw any further conclusions and clinical outcome measures and tumour responses to the vaccines are still missing.

OriginalsprogEngelsk
TidsskriftVaccine
Vol/bind36
Udgave nummer45
Sider (fra-til)6594-6605
Antal sider12
ISSN0264-410X
DOI
StatusUdgivet - 29 okt. 2018

ID: 56133083